Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 86 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Oxybutynin hydrochloride for treating neurogenic detrusor overactivity	Oxybutynin hydrochloride (Vesoxx)	Neurogenic detrusor overactivity	Neurology , Urology	2022	View \| Download
Opicapone adjuvant for the treatment of idiopathic Parkinson's disease	Opicapone (Ongentys)	Parkinson's disease	Neurology	2023	View \| Download
Omaveloxolone for the treatment of Friedreich's ataxia	Omaveloxolone	Friedreich's ataxia	Genetic Disorders , Neurology	2023	View \| Download
Ofatumumab for relapsing multiple sclerosis	Ofatumumab (Arzerra)	Multiple sclerosis (MS)	Neurology	2019	View \| Download
Ocrelizumab (subcutaneous) for the treatment of primary progressive or relapsing multiple sclerosis	Ocrelizumab (Ocrevus;2H7v114)	Multiple sclerosis (MS)	Neurology	2023	View \| Download
Neridronic Acid (Nerixia) for Complex Regional Pain Syndrome	Neridronic acid	Complex regional pain syndrome (CRPS)	Neurology	2017	View \| Download
Natalizumab biosimilar for treating relapsing-remitting multiple sclerosis	Natalizumab biosimilar (PB006)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis	Natalizumab (BG00002; Tysabri; Antegren; AN-100226; ELND-002)	Multiple sclerosis (MS)	Neurology	2021	View \| Download
Mirabegron for neurogenic detrusor overactivity in people aged 3 to 17 years	Mirabegron	Neurogenic detrusor overactivity	Neurology , Urology	2022	View \| Download
Mexiletine for the Symptomatic Treatment of Myotonic Disorders – First Line	Mexiletine hydrochloride (Namuscla)	Myotonia	Musculoskeletal System , Neurology	2018	View \| Download